Primary Objective: To compare overall survival (OS) from the time of the time of randomization between the treatment and control groups.~Secondary Objective(s)~To compare the extra-CNS PFS2 (EC-PFS2), defined as the time to extracranial disease progression on second line systemic therapy or death from the first day of local consolidative radiation therapy (treatment group) or from the start of second line therapy (control group).~To evaluate time to initiation of second line systemic therapy or palliative care after completion of local consolidative therapy in the treatment group~To compare the toxicities in the treatment and control groups;~To compare overall progression free survival from the time of the first day of local consolidative radiation therapy for the treatment group and from the start of second line therapy for the control group~To compare the pattern of next progression on second line therapy in the treatment group vs the control group.~To evaluate local progression in lesions treated with local consolidative radiation therapy.
This is a randomized phase II study designed to evaluate the effect of local consolidative radiation therapy (LCT) to all sites of oligoprogressive disease in patients with metastatic non-small cell lung carcinoma who have progressed through first line systemic therapy containing an immune checkpoint inhibitor (ICI).